Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab
- PMID: 25824512
- DOI: 10.1038/nrcardio.2015.51
Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab
Comment on
-
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Clinical Trial.
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.
Similar articles
-
Promising new therapies for the treatment of hypercholesterolemia.Expert Opin Biol Ther. 2016;16(5):609-18. doi: 10.1517/14712598.2016.1148136. Epub 2016 Feb 15. Expert Opin Biol Ther. 2016. PMID: 26822080 Review.
-
PCSK9 Inhibitors and Cardiovascular Events.N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222. N Engl J Med. 2015. PMID: 26287855 No abstract available.
-
PCSK9 Inhibitors and Cardiovascular Events.N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222. N Engl J Med. 2015. PMID: 26287854 No abstract available.
-
Lowering LDL cholesterol is good, but how and in whom?N Engl J Med. 2015 Apr 16;372(16):1564-5. doi: 10.1056/NEJMe1502192. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773740 No abstract available.
-
[Lipid control in high-risk patients: focus on PCSK9 inhibitors].G Ital Cardiol (Rome). 2015 Jan;16(1):44-51. doi: 10.1714/1776.19250. G Ital Cardiol (Rome). 2015. PMID: 25689751 Review. Italian.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical